Cargando…

Tocilizumab in COVID-19: finding the optimal route and dose

Detalles Bibliográficos
Autores principales:	Jain, Siddharth, Jain, Sanjay, Sharma, Shefali Khanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498201/ https://www.ncbi.nlm.nih.gov/pubmed/32964209 http://dx.doi.org/10.1016/S2665-9913(20)30334-9

Ejemplares similares

Tocilizumab in COVID-19: finding the optimal route and dose – Authors' reply
por: Guaraldi, Giovanni, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Mourad, Jean-Jacques, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Lipworth, Brian J, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Piano, Salvatore, et al.
Publicado: (2020)

Predictors of COVID-19 severity and outcomes in Indian patients with rheumatic diseases: a prospective cohort study
por: Mathew, Jithin, et al.
Publicado: (2023)

Tocilizumab for severe COVID-19 pneumonia – Authors' reply
por: Guaraldi, Giovanni, et al.
Publicado: (2020)

Tocilizumab in COVID-19 therapy: who benefits, and how?
por: Yang, Chengliang, et al.
Publicado: (2021)

Tocilizumab in COVID-19 therapy: who benefits, and how?
por: Neumann, Avidan U, et al.
Publicado: (2021)

Ovarian dysfunction with moderate-dose intravenous cyclophosphamide (modified NIH regimen) and mycophenolate mofetil in young adults with severe lupus: a prospective cohort study
por: Sharma, Shefali Khanna, et al.
Publicado: (2020)

Successful treatment of a critical COVID-19 patient with tocilizumab
por: Tsao, Shih-Ming, et al.
Publicado: (2021)

WHO prequalified tocilizumab and vaccine boosters against COVID-19
por: Rahimi, Farid, et al.
Publicado: (2022)

First, Do No Harm: Caution Against Use of Tocilizumab in COVID-19
por: Mastroianni, Fiore
Publicado: (2020)

Tocilizumab in COVID-19 therapy: who benefits, and how? – Authors' reply
por: Horby, Peter, et al.
Publicado: (2021)

Corticosteroid Plus Tocilizumab in COVID-19: When Two Is Better Than One
por: Kow, Chia Siang, et al.
Publicado: (2021)

Successful treatment of tocilizumab and ivermectin for a patient with ARDS due to COVID-19
por: Chuang, Tzu-Yi, et al.
Publicado: (2021)

2648. Taming the Cytokine Storm: Baricitinib versus Tocilizumab for COVID-19 Hyperinflammation
por: Radziszewski, Skyler, et al.
Publicado: (2023)

Prognostic Role of Measurement of Renal Resistive Index in Systemic Sclerosis
por: Sharma, Shefali Khanna, et al.
Publicado: (2021)

‘Test, re-test, re-test’: using inaccurate tests to greatly increase the accuracy of COVID-19 testing
por: Ramdas, Kamalini, et al.
Publicado: (2020)

Postnatally-Acquired COVID-19 in Central India
por: Jain, Jenisha, et al.
Publicado: (2020)

Heart-Kidney Transplanted patient affected by COVID-19 pneumonia treated with tocilizumab on top of immunosuppressive maintenance therapy
por: Ammirati, Enrico, et al.
Publicado: (2020)

Impact of Interleukin-6 Receptor Blockade With Tocilizumab on Cardiac Injury in Patients With COVID-19: A Retrospective Cohort Study
por: Weber, Brittany N, et al.
Publicado: (2021)

“Efficacy of tocilizumab in treatment of COVID-19 pneumonia: A case–control study from a tertiary care hospital”
por: Barthwal, M. S., et al.
Publicado: (2023)

Questioning Tocilizumab Use in Hospitalized Patients With Coronavirus Disease 2019
por: Mombrun, Martin, et al.
Publicado: (2021)

Comparison of two doses of leucovorin in severe low-dose methotrexate toxicity – a randomized controlled trial
por: Bhargava, Mudit, et al.
Publicado: (2023)

Tocilizumab for the treatment of paraneoplastic inflammatory syndrome associated with angiomatoid fibrous histiocytoma
por: Eberst, Lauriane, et al.
Publicado: (2020)

Stages or phenotypes? A critical look at COVID-19 pathophysiology
por: Jain, Amit, et al.
Publicado: (2020)

Olfactory Nasal Nitric Oxide Link in COVID-19: A Marker of Neurogenesis or Risk Factor for Chronic Rhinosinusitis?
por: Jain, Amit
Publicado: (2021)

Presence of virulence determinants amongst Staphylococcus aureus isolates from nasal colonization, superficial & invasive infections
por: Bhatty, Minny, et al.
Publicado: (2013)

Revisiting dose-finding of monoclonal antibodies in migraine
por: Al-Hassany, Linda, et al.
Publicado: (2023)

Optimal dosing & time: Issues to get hydroxychloroquine safety & efficacy against COVID-19/SARS-CoV-2
por: Neves, Fabricio Souza
Publicado: (2020)

Necrotizing fasciitis with slow progression in a patient with rheumatoid arthritis receiving tocilizumab
por: Goto, Kazuya, et al.
Publicado: (2022)

Apoptosis and pericyte loss in alveolar capillaries in COVID-19 infection: choice of markers matters
por: Jain, Amit, et al.
Publicado: (2020)

Standard Dose Ivermectin for COVID-19
por: Buonfrate, Dora, et al.
Publicado: (2021)

Tocilizumab in patients with COVID-19: which patient, time, and dose?
por: Hasanin, Ahmed, et al.
Publicado: (2021)

Tocilizumab in Large Vessel Vasculitis – Different Routes of Administration
por: Schmalzing, Marc, et al.
Publicado: (2018)

High Circulating Plasma Soluble Receptor for Advanced Glycation End-Products in Early COVID-19–associated Acute Respiratory Distress Syndrome: Pathophysiological Significance?
por: Jain, Amit
Publicado: (2021)

Viral RNA Shedding and Transmission Potential of Asymptomatic and Pauci-symptomatic COVID-19 Patients
por: Gupta, Ajay, et al.
Publicado: (2021)

Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis
por: te Brake, Lindsey H. M., et al.
Publicado: (2019)

Dexmedetomidine: another arrow in the quiver to fight COVID-19 in intensive care units
por: Jain, Amit, et al.
Publicado: (2021)

VITT and Second Doses of Covid-19 Vaccine
por: Lacy, Joanne, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7p1tvspp6ugi1c81jc32767m4k